Ruth B. Schneider, M.D.

(Pronouns: she/her/hers)

Contact Information

Phone Numbers

Appointment: (585) 341-7500

A member of the University of Rochester Medical Faculty Group

An Accountable Health Partner

Accepting New Patients

Locations

Clinton Crossings Neurology
919 Westfall Rd, Ste 100
Bldg C
Rochester, NY 14618-2628

Neurology: (585) 341-7500

Faculty Appointments

Associate Professor - Department of Neurology , Movement Disorders (SMD)
Associate Professor - Center for Health and Technology - Joint

Patient Care Setting

Neurology

Biography

Dr. Schneider is a board-certified neurologist with expertise in movement disorders. She graduated from Brown University in 2006 and received her MD from the University of Rochester School of Medicine and Dentistry in 2010. She completed her neurology residency in 2014 and a movement disorders fellowship in 2015, both at the University of Rochester. She joined the faculty in 2015 and specializes in the care of patients with movement disorders, including Parkinson's disease, Huntington's disease, and essential tremor. She is the Director of our Huntington's Disease Society of America Center of Excellence. Her research focuses on the development of digital measures of disease, participant-centered remote research designs, and the neuropsychiatric manifestations of Parkinson's disease.

Credentials

Education

2010
MD | University of Rochester School of Medicine/Dentistry

Post-doctoral Training & Residency

07/01/2014 - 06/30/2015
Fellowship in Movement Disorders at University of Rochester Medical Center

07/01/2011 - 06/30/2014
Residency in Neurology at University of Rochester Medical Center

06/16/2010 - 06/30/2011
Internship in Internal Medicine at University of Rochester Medical Center

VIEW ALL

Awards

2021 - 2022
Women Leading in Neurology Program
Sponsor: American Academy of Neurology

Clinical Trials

The Parkinson's Progression Markers Initiative (PPMI) 2.0 Clinical -Establishing a Deeply Phenotyped PD Cohort

Lead Researcher: Ruth Schneider

The Parkinson Progression Marker Initiative 2.0 (PPMI 2.0) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression in study participants with manifest PD, prodromal PD, and healthy controls. The overall goal of the study is to identify markers of disease progression for use in clinical trials of therapies to reduce progression of PD disability.

View Study Details

Publications

Journal Articles

8/23/2023
Islam MS, Rahman W, Abdelkader A, Lee S, Yang PT, Purks JL, Adams JL, Schneider RB, Dorsey ER, Hoque E. "Using AI to measure Parkinson's disease severity at home." NPJ digital medicine.. 2023 Aug 23; 6(1):156. Epub 2023 Aug 23.

8/22/2023
Kadura S, Schneider RB. "Moving beyond alerts: Electronic health record strategies to improve inpatient Parkinson's disease care." Parkinsonism & related disorders.. 2023 Aug 22; :105819. Epub 2023 Aug 22.

8/5/2023
Schneider RB, Auinger P, Dobkin RD, Mills KA, Kulick-Soper CV, Myers TL, Korell M, Pontone GM, Nirenberg MJ. "Minor Phenomena in Parkinson's Disease-Prevalence, Associations, and Risk of Developing Psychosis." Journal of geriatric psychiatry and neurology.. 2023 Aug 5; :8919887231195220. Epub 2023 Aug 05.

Books & Chapters

2022
Chapter Title: Disorders of the Motor System
Book Title: Cecil Essentials of Medicine
Author List: Ruth B Schneider, Adolfo Ramirez-Zamora, Christopher G Tarolli
Edited By: Edward J. Wing, Fred J. Schiffman
Published By: Elsevier, Inc 2022

VIEW ALL PUBLICATIONS